

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Masanori MATSUI	05/27/2011
Tetsuya UCHIDA	06/06/2011
Hiroshi ODA	05/30/2011

RECEIVING PARTY DATA

Name:	NOF CORPORATION
Street Address:	20-3, Ebisu 4-chome
City:	Shibuya-ku, Tokyo
State/Country:	JAPAN
Postal Code:	150-6019

Name:	SAITAMA MEDICAL UNIVERSITY
Street Address:	38, Morohongoh, Moroyama-machi
City:	Iruma-gun, Saitama
State/Country:	JAPAN
Postal Code:	350-0495

Name:	JAPAN as represented by DIRECTOR-GENERAL of National Institute of Infectious Diseases
Street Address:	1-23-1, Toyama
City:	Shinjuku-ku, Tokyo
State/Country:	JAPAN
Postal Code:	162-8640

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13131560

CORRESPONDENCE DATA

501587908

**PATENT
 REEL: 026556 FRAME: 0125**

OP \$40.00 13131560

Fax Number: (202)293-7860
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 202-293-7060
Email: kmatsumoto@sughrue.com
Correspondent Name: SUGHRUE MION, PLLC
Address Line 1: 2100 Pennsylvania Avenue, NW
Address Line 2: Suite 800
Address Line 4: Washington, DISTRICT OF COLUMBIA 20037

ATTORNEY DOCKET NUMBER:

Q124730

NAME OF SUBMITTER:

Kazusa Matsumoto, New Appl. Specialist

Total Attachments: 2

source=Q124730_ASSIGNMENT_AS_FILED#page1.tif

source=Q124730_ASSIGNMENT_AS_FILED#page2.tif

ASSIGNMENT

Whereas, I/we,

<u>Name</u>	<u>Address</u>
1) Masanori MATSUI	c/o Saitama Medical University, 38, Morohongoh, Moroyama-machi, Iruma-gun, Saitama 350-0495 Japan
2) Tetsuya UCHIDA	c/o National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo 162-8640 Japan
3) Hiroshi ODA	c/o NOF CORPORATION, 3-3 Chidori-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0865 Japan

hereinafter called assignor(s), have invented certain improvements in
CYTOTOXIC T CELL EPI TOPE PEPTIDE FOR SARS CORONAVIRUS, AND USE THEREOF

and executed an application for Letters Patent of the United States of America therefor on even date herewith unless otherwise indicated below:

filed on May 26, 2011, Serial No. 13/131560; and

Whereas

NOF CORPORATION

20-3, Ebisu 4-chome,
Shibuya-ku, Tokyo 150-6019 Japan

and, **SAITAMA MEDICAL UNIVERSITY**

38, Morohongoh, Moroyama-machi,
Iruma-gun, Saitama 350-0495 Japan

and, **JAPAN as represented by DIRECTOR-GENERAL of National Institute of Infectious Diseases**

1-23-1, Toyama,
Shinjuku-ku, Tokyo 162-8640 Japan


(assignee), desires to acquire the entire right, title and interest in the application and invention, and to any United States patents to be obtained therefor;

NOW THEREFORE, be it known that, for good and valuable consideration from assignee, the receipt of which is hereby acknowledged, I/WE, as assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the assignee, its lawful successors and assigns, MY/OUR entire right, title, and interest in and to this invention and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof; and I/WE hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue all Letters Patent for this invention to assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY further covenant and agree that I/WE will, without further consideration, communicate with assignee, its successors and assigns, any facts known to ME/US respecting this invention and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver all papers that may be necessary or desirable to perfect the title to this invention in said assignee, its successors and assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States, it being understood that any expense incident to the execution of such papers shall be borne by the assignee, its successors and assigns.

INVENTORS

DATE SIGNED

1):		<u>May 27, 2011</u>
Name:	Masanori MATSUI	
2):	Tetsuya UCHIDA	
Name:	Tetsuya UCHIDA	
3):	Hiroshi ODA	
Name:	Hiroshi ODA	

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. § 261)

ASSIGNMENT

Whereas, I/we,

<u>Name</u>	<u>Address</u>
1) Masanori MATSUI	c/o Saitama Medical University, 38, Morohongoh, Moroyama-machi, Iruma-gun, Saitama 350-0495 Japan
2) Tetsuya UCHIDA	c/o National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo 162-8640 Japan
3) Hiroshi ODA	c/o NOF CORPORATION, 3-3 Chidori-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0865 Japan

hereinafter called assignor(s), have invented certain improvements in
CYTOTOXIC T CELL EPI TOPE PEPTIDE FOR SARS CORONAVIRUS, AND USE THEREOF

and executed an application for Letters Patent of the United States of America therefor on even date herewith unless otherwise indicated below:

filed on May 26, 2011, Serial No. 13/131560; and

Whereas

NOF CORPORATION

20-3, Ebisu 4-chome,
Shibuya-ku, Tokyo 150-6019 Japan

and, **SAITAMA MEDICAL UNIVERSITY**

38, Morohongoh, Moroyama-machi,
Iruma-gun, Saitama 350-0495 Japan

and, **JAPAN as represented by DIRECTOR-GENERAL of National Institute of Infectious Diseases**

1-23-1, Toyama,
Shinjuku-ku, Tokyo 162-8640 Japan

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to any United States patents to be obtained therefor;

NOW THEREFORE, be it known that, for good and valuable consideration from assignee, the receipt of which is hereby acknowledged, I/WE, as assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the assignee, its lawful successors and assigns, MY/OUR entire right, title, and interest in and to this invention and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof; and I/WE hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue all Letters Patent for this invention to assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY further covenant and agree that I/WE will, without further consideration, communicate with assignee, its successors and assigns, any facts known to ME/US respecting this invention and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver all papers that may be necessary or desirable to perfect the title to this invention in said assignee, its successors and assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States, it being understood that any expense incident to the execution of such papers shall be borne by the assignee, its successors and assigns.

INVENTORS

DATE SIGNED

1):	Name: <u>Masanori MATSUI</u>	
2):	Name: <u>Tetsuya UCHIDA</u>	<u>June 6, 2011</u>
3):	Name: <u>Hiroshi ODA</u>	<u>May 30, 2011</u>

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. § 261)